Iovance Biotherapeutics (IOVA) EBITDA Margin (2023 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly EBITDA Margin of 113.46% for Q1 2026, up 13231.0% year-over-year from N/an in Q1 2025, and down 34.02% quarter-over-quarter from 84.66% in Q4 2025.
Powered by 
Analysis
Iovance Biotherapeutics (IOVA) EBITDA Margin (2023 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported EBITDA Margin for 4 consecutive years, with 113.46% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA Margin rose 13231.0% year-over-year to 113.46%; the TTM figure through Mar 2026 stood at 127.16% (up 6034.0% YoY), while the FY2025 annual figure was 153.08%, up 8785.0% from the prior year.
- EBITDA Margin fell to 113.46% in Q1 2026 per IOVA's latest filing, from 84.66% in the prior quarter.
- Across five years, EBITDA Margin topped out at 84.66% in Q4 2025 and bottomed at 46254.62% in Q2 2023.
- Historically, EBITDA Margin has averaged 9540.38% across 4 years, with a median of 217.77% in 2025.
- Annual changes were most pronounced in 2024 — EBITDA Margin surged 4592699 bps — and 2025, when it jumped 1142 bps.
- Iovance Biotherapeutics' EBITDA Margin stood at 25156.85% in 2023, then jumped by 100 bps to 117.48% in 2024, then climbed by 28 bps to 84.66% in 2025, then plunged by 34 bps to 113.46% in 2026.
- Business Quant data shows IOVA's EBITDA Margin at 113.46% in Q1 2026, 84.66% in Q4 2025, and 140.69% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Iovance Biotherapeutics | 3.95 Bn | 3.66 Bn | 55.72 Mn | -52.26% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -52.26% |
| Mar 31, 2026 | -113.46% |
| Dec 31, 2025 | -84.66% |
| Sep 30, 2025 | -140.69% |
| Jun 30, 2025 | -189.78% |
| Mar 31, 2025 | -245.76% |
| Dec 31, 2024 | -117.48% |
| Sep 30, 2024 | -152.11% |
| Jun 30, 2024 | -327.63% |
| Mar 31, 2024 | -16,464.62% |
| Dec 31, 2023 | -25,156.85% |
| Sep 30, 2023 | -25,236.89% |
| Jun 30, 2023 | -46,254.62% |